Concepedia

Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms

Mark W. Linder, Stephen W. Looney, Jesse E. Adams, Nancy Johnson, Deborah M. Antonino-Green, Nichole Lacefield, Bonny L. Bukaveckas, Roland Valdes

Journal of Thrombosis and Thrombolysis · 2002 · 96 citations · 24 references

Concepts

MedicinePharmacokineticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsClinical Implementation Of PharmacogeneticsClinical Implementation Of PharmacogenomicsDose SelectionDrug Metabolism GeneticsPersonalized Drug DosingPharmacogenetic TestingCyp2c9 GenotypingCytochrome P450 Genotype EffectsGenotype-based Drug DosingGenotype-guided AnticoagulationWarfarin Dose Optimization

References

24

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Medicine, Pharmacokinetics, Pharmacology +12

Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy

Mitchell K. Higashi · JAMA · 2002 · 1.1K citations

Medicine, Genetics, Pharmacology +17

NOTE ON AN EXACT TREATMENT OF CONTINGENCY, GOODNESS OF FIT AND OTHER PROBLEMS OF SIGNIFICANCE

G. H. Freeman, John H. Halton · Biometrika · 1951 · 878 citations

Education, Biostatistics, Statistics +10

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

Allan E. Rettie, Kenneth R. Korzekwa, Kent L. Kunze et al. · Chemical Research in Toxicology · 1992 · 602 citations

Medicine, Pharmacology, Toxicology +17

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

Theresa H. Sullivan-Klose, Burhan I. Ghanayem, Douglas A. Bell et al. · Pharmacogenetics · 1996 · 587 citations

Medicine, Genetics, Pharmacology +17